GlaxoSmithKline PLC Net Worth
GlaxoSmithKline PLC Net Worth Breakdown | GSK |
GlaxoSmithKline PLC Net Worth Analysis
GlaxoSmithKline PLC's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including GlaxoSmithKline PLC's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of GlaxoSmithKline PLC's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform GlaxoSmithKline PLC's net worth analysis. One common approach is to calculate GlaxoSmithKline PLC's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares GlaxoSmithKline PLC's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing GlaxoSmithKline PLC's net worth. This approach calculates the present value of GlaxoSmithKline PLC's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of GlaxoSmithKline PLC's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate GlaxoSmithKline PLC's net worth. This involves comparing GlaxoSmithKline PLC's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into GlaxoSmithKline PLC's net worth relative to its peers.
Enterprise Value |
|
To determine if GlaxoSmithKline PLC is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlaxoSmithKline PLC's net worth research are outlined below:
| GlaxoSmithKline PLC has a strong financial position based on the latest SEC filings | |
| Latest headline from globenewswire.com: ROSEN, A LEADING NATIONAL FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action GSK |
GlaxoSmithKline PLC Quarterly Good Will |
|
GlaxoSmithKline PLC uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlaxoSmithKline PLC ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlaxoSmithKline PLC's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
GlaxoSmithKline PLC Target Price Consensus
GlaxoSmithKline target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. GlaxoSmithKline PLC's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Buy |
Most GlaxoSmithKline analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand GlaxoSmithKline stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of GlaxoSmithKline PLC ADR, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGlaxoSmithKline PLC Target Price Projection
GlaxoSmithKline PLC's current and average target prices are 39.24 and 45.07, respectively. The current price of GlaxoSmithKline PLC is the price at which GlaxoSmithKline PLC ADR is currently trading. On the other hand, GlaxoSmithKline PLC's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
GlaxoSmithKline PLC Market Quote on 23rd of March 2025
Target Price
Analyst Consensus On GlaxoSmithKline PLC Target Price
Know GlaxoSmithKline PLC's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlaxoSmithKline PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlaxoSmithKline PLC ADR backward and forwards among themselves. GlaxoSmithKline PLC's institutional investor refers to the entity that pools money to purchase GlaxoSmithKline PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 5.7 M | Hotchkis & Wiley Capital Management Llc | 2024-12-31 | 4.6 M | Grantham, Mayo, Van Otterloo & Co., Llc | 2024-12-31 | 4.2 M | Equity Investment Corp | 2024-12-31 | 4 M | Eversept Partners, Llc | 2024-12-31 | 3.7 M | Renaissance Technologies Corp | 2024-12-31 | 2.8 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 2.6 M | Camber Capital Management Llc | 2024-12-31 | 2.5 M | Armistice Capital, Llc | 2024-12-31 | 2.4 M | Dodge & Cox | 2024-12-31 | 68.4 M | Fmr Inc | 2024-12-31 | 52.8 M |
Follow GlaxoSmithKline PLC's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 79.85 B.Market Cap |
|
Project GlaxoSmithKline PLC's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.07 | 0.07 | |
| Return On Capital Employed | 0.11 | 0.10 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.19 | 0.18 |
When accessing GlaxoSmithKline PLC's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures GlaxoSmithKline PLC's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GlaxoSmithKline PLC's profitability and make more informed investment decisions.
Evaluate GlaxoSmithKline PLC's management efficiency
GlaxoSmithKline PLC ADR has Return on Asset of 0.0653 % which means that on every $100 spent on assets, it made $0.0653 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.228 %, implying that it generated $0.228 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.07. The value of Return On Capital Employed is expected to slide to 0.10. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.5 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.21 | 3.37 | |
| Tangible Book Value Per Share | (2.31) | (2.19) | |
| Enterprise Value Over EBITDA | 10.23 | 17.07 | |
| Price Book Value Ratio | 4.02 | 3.81 | |
| Enterprise Value Multiple | 10.23 | 17.07 | |
| Price Fair Value | 4.02 | 3.81 | |
| Enterprise Value | 61.1 B | 44.8 B |
Leadership at GlaxoSmithKline PLC emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 2.3825 | Revenue | Quarterly Revenue Growth 0.008 | Revenue Per Share | Return On Equity |
GlaxoSmithKline PLC Corporate Filings
6K | 21st of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
FWP | 7th of March 2025 A written communication used by offering participants to offer securities to the public or to solicit securities transactions. | ViewVerify |
GlaxoSmithKline PLC Earnings Estimation Breakdown
The calculation of GlaxoSmithKline PLC's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of GlaxoSmithKline PLC is estimated to be 1.0125 with the future projection ranging from a low of 0.9568 to a high of 1.0683. Please be aware that this consensus of annual earnings estimates for GlaxoSmithKline PLC ADR is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.96 Lowest | Expected EPS | 1.07 Highest |
GlaxoSmithKline PLC Earnings Projection Consensus
Suppose the current estimates of GlaxoSmithKline PLC's value are higher than the current market price of the GlaxoSmithKline PLC stock. In this case, investors may conclude that GlaxoSmithKline PLC is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and GlaxoSmithKline PLC's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 8 | 88.23% | 0.5792 | 1.0125 | 1.61 |
GlaxoSmithKline PLC Earnings History
Earnings estimate consensus by GlaxoSmithKline PLC ADR analysts from Wall Street is used by the market to judge GlaxoSmithKline PLC's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only GlaxoSmithKline PLC's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.GlaxoSmithKline PLC Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of GlaxoSmithKline PLC's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
GlaxoSmithKline PLC Earnings per Share Projection vs Actual
Actual Earning per Share of GlaxoSmithKline PLC refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering GlaxoSmithKline PLC ADR predict the company's earnings will be in the future. The higher the earnings per share of GlaxoSmithKline PLC, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.GlaxoSmithKline PLC Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as GlaxoSmithKline PLC, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of GlaxoSmithKline PLC should always be considered in relation to other companies to make a more educated investment decision.GlaxoSmithKline Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact GlaxoSmithKline PLC's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-05 | 2024-12-31 | 0.4876 | 0.5792 | 0.0916 | 18 | ||
2024-10-30 | 2024-09-30 | 1.23 | 1.29 | 0.06 | 4 | ||
2024-07-31 | 2024-06-30 | 0.99 | 1.1 | 0.11 | 11 | ||
2024-05-01 | 2024-03-31 | 0.91 | 1.09 | 0.18 | 19 | ||
2024-01-31 | 2023-12-31 | 0.76 | 0.72 | -0.04 | 5 | ||
2023-11-01 | 2023-09-30 | 1.14 | 1.28 | 0.14 | 12 | ||
2023-07-26 | 2023-06-30 | 0.87 | 0.97 | 0.1 | 11 | ||
2023-04-26 | 2023-03-31 | 0.82 | 0.9 | 0.08 | 9 | ||
2023-02-01 | 2022-12-31 | 0.5 | 0.61 | 0.11 | 22 | ||
2022-11-02 | 2022-09-30 | 0.96 | 1.1 | 0.14 | 14 | ||
2022-07-27 | 2022-06-30 | 0.73 | 0.87 | 0.14 | 19 | ||
2022-04-29 | 2022-03-31 | 0.93 | 1.09 | 0.16 | 17 | ||
2022-02-09 | 2021-12-31 | 0.81 | 0.86 | 0.05 | 6 | ||
2021-10-27 | 2021-09-30 | 1.01 | 1.26 | 0.25 | 24 | ||
2021-07-28 | 2021-06-30 | 0.64 | 0.98 | 0.34 | 53 | ||
2021-04-28 | 2021-03-31 | 0.76 | 0.79 | 0.03 | 3 | ||
2021-02-03 | 2020-12-31 | 0.8 | 0.77 | -0.03 | 3 | ||
2020-10-28 | 2020-09-30 | 1 | 1.25 | 0.25 | 25 | ||
2020-07-29 | 2020-06-30 | 0.64 | 0.57 | -0.07 | 10 | ||
2020-04-29 | 2020-03-31 | 0.89 | 1.2 | 0.31 | 34 | ||
2020-02-05 | 2019-12-31 | 0.84 | 0.8 | -0.04 | 4 | ||
2019-10-30 | 2019-09-30 | 1.06 | 1.19 | 0.13 | 12 | ||
2019-07-24 | 2019-06-30 | 0.78 | 0.99 | 0.21 | 26 | ||
2019-05-01 | 2019-03-31 | 0.81 | 0.98 | 0.17 | 20 | ||
2019-02-06 | 2018-12-31 | 0.84 | 1.01 | 0.17 | 20 | ||
2018-10-31 | 2018-09-30 | 1.1 | 1.15 | 0.05 | 4 | ||
2018-07-25 | 2018-06-30 | 0.98 | 0.99 | 0.01 | 1 | ||
2018-04-25 | 2018-03-31 | 0.86 | 0.86 | 0.0 | 0 | ||
2018-02-07 | 2017-12-31 | 0.84 | 0.89 | 0.05 | 5 | ||
2017-10-25 | 2017-09-30 | 1.04 | 1.06 | 0.02 | 1 | ||
2017-07-26 | 2017-06-30 | 0.86 | 0.88 | 0.02 | 2 | ||
2017-04-26 | 2017-03-31 | 0.79 | 0.79 | 0.0 | 0 | ||
2017-02-08 | 2016-12-31 | 0.8 | 0.81 | 0.01 | 1 | ||
2016-10-26 | 2016-09-30 | 0.93 | 1.06 | 0.13 | 13 | ||
2016-07-27 | 2016-06-30 | 0.69 | 0.86 | 0.17 | 24 | ||
2016-04-27 | 2016-03-31 | 0.65 | 0.69 | 0.04 | 6 | ||
2016-02-03 | 2015-12-31 | 0.61 | 0.69 | 0.08 | 13 | ||
2015-10-28 | 2015-09-30 | 0.73 | 0.88 | 0.15 | 20 | ||
2014-10-22 | 2014-09-30 | 0.5 | 1.16 | 0.66 | 132 | ||
2014-02-05 | 2013-12-31 | 1.2 | 1.21 | 0.01 | 0 | ||
2013-02-06 | 2012-12-31 | 0.9 | 1.3 | 0.4 | 44 | ||
2012-07-25 | 2012-06-30 | 1.08 | 1.04 | -0.04 | 3 | ||
2012-04-25 | 2012-03-31 | 1.14 | 1.06 | -0.08 | 7 | ||
2012-02-07 | 2011-12-31 | 0.83 | 0.98 | 0.15 | 18 | ||
2011-10-26 | 2011-09-30 | 1.16 | 1.13 | -0.03 | 2 | ||
2011-07-26 | 2011-06-30 | 0.96 | 0.89 | -0.07 | 7 | ||
2011-04-27 | 2011-03-31 | 1.24 | 1.19 | -0.05 | 4 | ||
2008-02-07 | 2007-12-31 | 1.05 | 1.25 | 0.2 | 19 | ||
2007-10-24 | 2007-09-30 | 1.19 | 1.19 | 0.0 | 0 | ||
2007-07-25 | 2007-06-30 | 1.18 | 1.18 | 0.0 | 0 | ||
2007-04-25 | 2007-03-31 | 1.31 | 1.33 | 0.02 | 1 | ||
2007-02-08 | 2006-12-31 | 1.05 | 1.0 | -0.05 | 4 | ||
2006-02-08 | 2005-12-31 | 0.81 | 0.86 | 0.05 | 6 | ||
2005-10-27 | 2005-09-30 | 0.96 | 0.95 | -0.01 | 1 | ||
2005-04-28 | 2005-03-31 | 1.04 | 1.0 | -0.04 | 3 | ||
2005-02-10 | 2004-12-31 | 0.84 | 0.81 | -0.03 | 3 | ||
2004-10-28 | 2004-09-30 | 0.89 | 0.99 | 0.1 | 11 | ||
2004-07-27 | 2004-06-30 | 0.94 | 0.91 | -0.03 | 3 | ||
2004-04-29 | 2004-03-31 | 0.86 | 0.89 | 0.03 | 3 | ||
2004-02-06 | 2003-12-31 | 0.81 | 0.68 | -0.13 | 16 | ||
2003-10-22 | 2003-09-30 | 0.77 | 0.83 | 0.06 | 7 | ||
2003-07-23 | 2003-06-30 | 0.86 | 0.98 | 0.12 | 13 | ||
2003-04-30 | 2003-03-31 | 0.74 | 0.86 | 0.12 | 16 | ||
2003-02-12 | 2002-12-31 | 0.82 | 0.81 | -0.01 | 1 | ||
2002-10-23 | 2002-09-30 | 0.64 | 0.64 | 0.0 | 0 | ||
2002-07-25 | 2002-06-30 | 0.82 | 0.81 | -0.01 | 1 | ||
2002-04-25 | 2002-03-31 | 0.67 | 0.68 | 0.01 | 1 | ||
2002-02-14 | 2001-12-31 | 0.73 | 0.74 | 0.01 | 1 | ||
2001-10-23 | 2001-09-30 | 0.56 | 0.57 | 0.01 | 1 | ||
2001-07-24 | 2001-06-30 | 0.71 | 0.71 | 0.0 | 0 | ||
2001-05-18 | 2001-03-31 | 0.56 | 0.59 | 0.03 | 5 | ||
2000-07-01 | 2000-06-30 | 1.12 | 0.65 | -0.47 | 41 | ||
2000-06-30 | 2000-03-31 | 0.89 | 0.52 | -0.37 | 41 | ||
2000-02-16 | 1999-12-31 | 1.15 | 1.11 | -0.04 | 3 | ||
1999-08-02 | 1999-06-30 | 1.05 | 1.04 | -0.01 | 0 | ||
1999-02-18 | 1998-12-31 | 1.06 | 1.16 | 0.1 | 9 | ||
1998-08-12 | 1998-06-30 | 0.99 | 0.96 | -0.03 | 3 | ||
1997-08-04 | 1997-06-30 | 1.19 | 1.2 | 0.01 | 0 | ||
1997-03-07 | 1996-12-31 | 1.13 | 1.06 | -0.07 | 6 | ||
1996-08-05 | 1996-06-30 | 1.05 | 1.11 | 0.06 | 5 | ||
1996-03-06 | 1995-12-31 | 1.02 | 1.06 | 0.04 | 3 | ||
1995-02-07 | 1994-12-31 | 0.9 | 0.99 | 0.09 | 10 | ||
1994-09-08 | 1994-06-30 | 0.81 | 0.74 | -0.07 | 8 | ||
1993-09-14 | 1993-06-30 | 0.82 | 0.88 | 0.06 | 7 |
GlaxoSmithKline PLC Corporate Directors
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile | |
| Charles Bancroft | Non-Executive Independent Director | Profile | |
| Vivienne Cox | Independent Non-Executive Director and Workforce Engagement Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.173 | Dividend Share 0.61 | Earnings Share 1.61 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.